These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22335429)

  • 1. Predicting drug candidate victims of drug-drug interactions, using microdosing.
    Croft M; Keely B; Morris I; Tann L; Lappin G
    Clin Pharmacokinet; 2012 Apr; 51(4):237-46. PubMed ID: 22335429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W; Kubitza D; Becka M
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers.
    Ridtitid W; Ratsamemonthon K; Mahatthanatrakul W; Wongnawa M
    J Clin Pharm Ther; 2007 Dec; 32(6):585-93. PubMed ID: 18021336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
    Arlander E; Ekström G; Alm C; Carrillo JA; Bielenstein M; Böttiger Y; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Nov; 64(5):484-91. PubMed ID: 9834040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
    Li C; Choi DH; Choi JS
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):99-108. PubMed ID: 22210483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
    Uchida S; Tanaka S; Namiki N
    Biopharm Drug Dispos; 2014 May; 35(4):228-36. PubMed ID: 24395703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
    Lam YW; Alfaro CL; Ereshefsky L; Miller M
    J Clin Pharmacol; 2003 Nov; 43(11):1274-82. PubMed ID: 14551182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
    Sigafoos JF; Bowers GD; Castellino S; Culp AG; Wagner DS; Reese MJ; Humphreys JE; Hussey EK; O'Connor Semmes RL; Kapur A; Tao W; Dobbins RL; Polli JW
    Drug Metab Dispos; 2012 Nov; 40(11):2090-101. PubMed ID: 22851617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein.
    Cho YA; Choi JS; Burm JP
    Pharmacol Rep; 2011; 63(4):1066-73. PubMed ID: 22001996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study.
    Maeda K; Takano J; Ikeda Y; Fujita T; Oyama Y; Nozawa K; Kumagai Y; Sugiyama Y
    Clin Pharmacol Ther; 2011 Aug; 90(2):263-70. PubMed ID: 21716273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
    Achira M; Suzuki H; Ito K; Sugiyama Y
    AAPS PharmSci; 1999; 1(4):E18. PubMed ID: 11741214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
    Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
    J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and elimination of quinine in healthy volunteers.
    Mirghani RA; Hellgren U; Bertilsson L; Gustafsson LL; Ericsson O
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):423-7. PubMed ID: 12920491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
    Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
    Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
    J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
    Kovarik JM; Dole K; Riviere GJ; Pommier F; Maton S; Jin Y; Lasseter KC; Schmouder RL
    J Clin Pharmacol; 2009 Feb; 49(2):212-8. PubMed ID: 19118083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.